Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):287-93. doi: 10.1212/WNL.0b013e3181af79e5.

2.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

3.

Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.

Henneman WJ, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H, Barkhof F.

Neurology. 2009 Mar 17;72(11):999-1007. doi: 10.1212/01.wnl.0000344568.09360.31.

4.

Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease.

Qiu A, Fennema-Notestine C, Dale AM, Miller MI; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Apr 15;45(3):656-61.

5.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

6.

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM.

Ann Neurol. 2009 Feb;65(2):176-83. doi: 10.1002/ana.21559.

7.

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.

Chou YY, Leporé N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Jun;46(2):394-410. doi: 10.1016/j.neuroimage.2009.02.015. Epub 2009 Feb 21.

8.

apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV.

J Clin Invest. 2008 Dec;118(12):4002-13. doi: 10.1172/JCI36663. Epub 2008 Nov 13.

9.

Frequent amyloid deposition without significant cognitive impairment among the elderly.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE.

Arch Neurol. 2008 Nov;65(11):1509-17. doi: 10.1001/archneur.65.11.1509.

10.

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO.

Arch Neurol. 2008 Oct;65(10):1304-9. doi: 10.1001/archneur.65.10.noc80013. Epub 2008 Aug 11.

PMID:
18695050
11.

Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.

Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha R; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2008 Sep;131(Pt 9):2443-54. doi: 10.1093/brain/awn146. Epub 2008 Jul 11.

12.

Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study.

Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D.

Neurology. 2008 Jul 15;71(3):202-9. doi: 10.1212/01.wnl.0000316197.04157.6f. Epub 2008 Jun 4.

PMID:
18525029
13.

Multiplicity of cerebrospinal fluid functions: New challenges in health and disease.

Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD.

Cerebrospinal Fluid Res. 2008 May 14;5:10. doi: 10.1186/1743-8454-5-10.

14.

Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.

Donahue JE, Johanson CE.

J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70. doi: 10.1097/NEN.0b013e31816a0dc8. Review. Erratum in: J Neuropathol Exp Neurol. 2008 Jun;67(6):634.

PMID:
18379441
15.

Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype.

Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Hulette CM, Vitek MP, Cohen RA.

Stroke. 2008 Mar;39(3):814-21. doi: 10.1161/STROKEAHA.107.493429. Epub 2008 Feb 7. Erratum in: Stroke. 2010 Aug;41(8):e551.

16.

PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative.

Shaw LM.

Neurosignals. 2008;16(1):19-23. Epub 2007 Dec 5. Review.

17.

Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure.

Wostyn P, Audenaert K, De Deyn PP.

Clin Neurol Neurosurg. 2008 Feb;110(2):101-9. Epub 2007 Dec 3. Review.

PMID:
18061341
18.

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L.

Alzheimers Dement. 2005 Jul;1(1):55-66.

19.

Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia.

Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, Aizenstein HJ, Meltzer CC, Liu Y, Toga AW, Becker JT.

Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):14-24.

20.

Biomarkers in preclinical Alzheimer's disease.

Chong MS, Lim WS, Sahadevan S.

Curr Opin Investig Drugs. 2006 Jul;7(7):600-7. Review.

PMID:
16869111

Supplemental Content

Support Center